Zirconia-Reinforced Glass Ionomer Versus Injectable Giomer in Class V Restorations

July 24, 2026 updated by: Mohamed Ayman Hamdy Ahmed, Cairo University

Clinical Performance of Zirconia-Reinforced Glass Ionomer Versus Injectable Giomer in Class V Restorations of Diabetic and Non Diabetic Patients: 18 Months Controlled Clinical Trial

This randomized controlled clinical trial aims to compare the clinical performance of zirconia-reinforced glass ionomer and injectable giomer restorations in Class V carious lesions among controlled type II diabetic against non-diabetics. One hundred Class V restorations will be allocated equally into four parallel groups according to restorative material and diabetic status. Clinical performance will be evaluated at baseline, 6, 12, and 18 months using the modified United States Public Health Service (USPHS) criteria. The primary outcome is restoration retention, while secondary outcomes include marginal adaptation, marginal discoloration, secondary caries, and postoperative sensitivity.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or Female participants from 22 to 55 years
  • Controlled diabetic and non-diabetic patients consulting the outpatient clinic
  • Patients categorized as moderate or high caries risk
  • Patients willing to provide informed consent
  • Co-operative patients agreeing to participate in the trial Inclusion Criteria for teeth
  • Teeth with class V carious lesion classified according to the International Caries Detection and Assessment System (ICDAS II) as ICDAS code (4) or ICDAS code (5)
  • Teeth with normal pulp vitality testing; no signs of inflammation or spontaneous pain before treatment

Exclusion Criteria:

  • Patients with spontaneous or elicited pain from caries.
  • Systemic illnesses other than diabetes.
  • Severe bruxism/clenching.
  • Temporomandibular joint disorders.
  • Inability to return for recall visits/ Refusal to participate in the study.
  • Pregnancy.
  • heavy smoking.
  • Lack of compliance.

Exclusion criteria for teeth

  • Teeth presenting with spontaneous or elicited pain
  • A lack of normal pulp vitality testing
  • Visible or clinical signs of pulpal/periapical inflammation before treatment.
  • Class V carious lesions that are not classified as ICDAS code (4) or ICDAS code (5).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Diabetic
Other: Zirconomer
Zirconia-reinforced glass ionomer restorative material (SHOFU)
Other: Beautifil Flow Plus X
Injectable giomer restorative material incorporating S-PRG technology (SHOFU)
Experimental: Non-diabetic
Other: Zirconomer
Zirconia-reinforced glass ionomer restorative material (SHOFU)
Other: Beautifil Flow Plus X
Injectable giomer restorative material incorporating S-PRG technology (SHOFU)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Restoration Retention
Time Frame: Baseline, 6 months, 12 months, and 18 months
Restoration retention assessed using the modified USPHS criteria
Baseline, 6 months, 12 months, and 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Marginal adaptation
Time Frame: Baseline, 6 months, 12 months, and 18 months
Using Modified USPHS Criteria
Baseline, 6 months, 12 months, and 18 months
Marginal discoloration
Time Frame: Baseline, 6 months, 12 months and 18 months
Using Modified USPHS Criteria
Baseline, 6 months, 12 months and 18 months
Secondary caries
Time Frame: Baseline, 6 months, 12 months and 18 months.
Using Modified USPHS Criteria
Baseline, 6 months, 12 months and 18 months.
Postoperative sensitivity
Time Frame: Baseline, 6 months, 12 months and 18 months.
Using Modified USPHS Criteria
Baseline, 6 months, 12 months and 18 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

June 1, 2028

Study Completion (Estimated)

January 1, 2029

Study Registration Dates

First Submitted

July 21, 2026

First Submitted That Met QC Criteria

July 24, 2026

First Posted (Actual)

July 28, 2026

Study Record Updates

Last Update Posted (Actual)

July 28, 2026

Last Update Submitted That Met QC Criteria

July 24, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Cons 3-7-5

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe